Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Assidicky R, Tokat UM, Tarman IO, Saatci O, et al. Breast Cancer Res Treat 2022 Mar 25. pii: 10.1007/s10549-022-06569.

Read + Share

Amedeo Smart

Independent Medical Education

Assidicky R, Tokat UM, Tarman IO, Saatci O, et al. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Breast Cancer Res Treat 2022 Mar 25. pii: 10.1007/s10549-022-06569.
PMID: 35338412